Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

被引：0
|
作者：
Garcia Vega, D. [1 ]
Cinza-Sanjurjo, S. [2 ]
Eiras, S. [3 ,4 ]
Gonzalez-Juanatey, J. R. [1 ]
机构：
[1] Univ Hosp Santiago de Compostela, Santiago De Compostela, Spain
[2] Ctr Salud Milladoiro, Area Sanitaria Santiago de Compostela, Santiago De Compostela, Spain
[3] Hlth Res Inst Santiago de Compostela, Santiago De Compostela, Spain
[4] CIBERCV, Santiago De Compostela, Spain
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2024年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：591 / 591
页数：1
相关论文
共 50 条
  • [21] Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
    Dorrin Zarrin Khat
    Mansoor Husain
    Current Diabetes Reports, 2018, 18
  • [22] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
    Vale, Catarina
    Lourenco, Ines Mariana
    Jordan, Gabriela
    Golovaty, Ilya
    Torres, Hugo
    Moin, Tannaz
    Buysschaert, Martin
    Neves, Joao Sergio
    Bergman, Michael
    DIABETES OBESITY & METABOLISM, 2024,
  • [23] SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
    Anson, Matthew
    Zhao, Sizheng S.
    Austin, Philip
    Ibarburu, Gema H.
    Malik, Rayaz A.
    Alam, Uazman
    DIABETOLOGIA, 2023, 66 (10) : 1869 - 1881
  • [24] SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
    Matthew Anson
    Sizheng S. Zhao
    Philip Austin
    Gema H. Ibarburu
    Rayaz A. Malik
    Uazman Alam
    Diabetologia, 2023, 66 : 1869 - 1881
  • [25] Impact of Endocrine E-Consultation on SGLT2i and GLP-1 RA Prescription
    Rasheed, Amna
    Kompala, Tejaswi
    Neinstein, Aaron B.
    DIABETES, 2021, 70
  • [26] Gaps in Guideline-Indicated Prescribing of GLP1RA/SGLT2i in Patients with T2DM and Cardiorenal Disease according to ADA Standards of Care
    Lingvay, Ildiko
    Bowen, Michael E.
    Mai, Christine
    Marble, Kelsea
    Pak, Jonathan
    Basit, Mujeeb A.
    DIABETES, 2023, 72
  • [27] Combined therapy with SGLT2i and GLP-1ra improves cardiovascular prognosis in a population with diabetes and overweigh or obesity. A real-world clinical practice study
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Gonzalez-Juanatey, J. R.
    Eiras, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [28] Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Clemmensen, K. K. B.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S30 - S30
  • [29] Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes
    Clemmensen, K. K. B.
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S29 - S29
  • [30] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
12345